CRISPR Therapeutics IPO
CRISPR Therapeutics is a gene editing company developing transformative medicines using CRISPR/Cas9 technology for serious diseases. The company focuses on treatments for blood disorders, cancer, and diabetes, with advanced programs in sickle cell disease and beta-thalassemia. Investors are drawn to its clinical leadership and broad therapeutic platform.
Key Facts
| Industry | Biotechnology |
| Founded | 2013 |
| Headquarters | Zug, Switzerland |
| Employees | ~500 |
| Website | crisprtx.com |
| Funding | Public company (NASDAQ: CRSP) |
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene editing company that develops transformative medicines using its proprietary CRISPR/Cas9 platform. The company focuses on developing treatments for serious diseases including sickle cell disease, beta-thalassemia, cancer, and diabetes. Their lead therapy, Casgevy (exagamglogene autotemcel), became the first CRISPR-based treatment approved by regulators in multiple countries.
The company operates through strategic partnerships, including a significant collaboration with Vertex Pharmaceuticals for developing CTX001 for blood disorders. CRISPR Therapeutics is also advancing CAR-T cell therapies for cancer treatment and exploring in vivo gene editing approaches. Their scientific leadership and robust pipeline have established them as one of the premier companies in the gene editing revolution.
IPO Status
CRISPR Therapeutics completed its IPO in October 2016, raising approximately $56 million on NASDAQ under the ticker CRSP. The Swiss-based company was among the early pioneers to bring CRISPR technology to public markets, generating significant interest from biotech investors. Since its IPO, CRISPR Therapeutics has achieved several important milestones, including advancing CTX001 (developed with Vertex Pharmaceuticals) for sickle cell disease and beta-thalassemia through late-stage clinical trials. The stock has experienced significant volatility typical of clinical-stage biotechs, with major movements often corresponding to clinical data releases and regulatory updates.
Competitors
Frequently Asked Questions
Does CRISPR Therapeutics have a stock?
Yes, CRISPR Therapeutics completed its IPO in October 2016. The company has been publicly traded on NASDAQ under the ticker CRSP for several years.
When is the CRISPR Therapeutics IPO date?
CRISPR Therapeutics already completed its IPO on October 19, 2016. The company is currently a publicly traded biotechnology stock on NASDAQ.
How can I buy CRISPR Therapeutics stock?
You can buy CRISPR Therapeutics stock through any brokerage account since it trades publicly on NASDAQ under the ticker CRSP. The shares are available for purchase during standard market hours.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts